Hot Keywords
Tumor Microenvironment Exosomes and Extracellular Vesicles Breast Cancer Metastasis Bone Metastasis Metastatic Renal Cell Carcinoma Lymph node metastasis Mesothelioma Hematological Malignancies Thyroid Cancer Liquid Biopsies Early Diagnosis Lung Cancer Brain Tumors Lymphoma Oncolytic Virus Cervical Cancer Cancer Stem Cells

Topic: Angiogenesis and Antiangiogenesis in Hematological Malignancies

A special issue of Journal of Cancer Metastasis and Treatment

ISSN 2454-2857 (Online), ISSN 2394-4722 (Print)

Submission deadline: 31 Dec 2021

Guest Editor(s)

  • Prof. Domenico Ribatti
    Department of Basic Medical Sciences, Neurosciences and Sensory Organs, University of Bari Medical School, Bari, Italy.

    Website | E-mail

Special Issue Introduction

It has been generally accepted that angiogenesis is involved in the pathogenesis of hematological malignancies, like acute and chronic leukemia, lymphoma, myelodysplastic syndromes, myeloproliferative neoplasms, and multiple myeloma. The extent of angiogenesis in the bone marrow is correlated with disease burden, prognosis, and treatment outcome. Reciprocal positive and negative interactions between tumor cells and bone marrow stromal cells, namely hematopoietic stem cells, fibroblasts, osteoblasts/osteoclasts, endothelial cells, endothelial progenitor cells, T cells, macrophages and mast cells, mediated by an array of cytokines, receptors and adhesion molecules, modulate the angiogenic response in hematological tumors. More recently, the pro-angiogenic role of the so-called “vascular niche” has been emphasized, indicating a site rich in blood vessels where endothelial cells and mural cells such as pericytes and smooth muscle cells create a microenvironment that affects the behavior of several stem and progenitor cells in hematological malignancies.

Anti-angiogenesis was proposed as a cancer therapy over 40 years ago, when Judah Folkman published in the New England Journal of Medicine a hypothesis that tumor growth is angiogenesis-dependent. Several preclinical and clinical trials are exploring the combination of various angiogenesis inhibitors in the treatment of hematological malignancies with other targeted therapies.

The following topics will be discussed in this special issue:

The bone marrow microenvironment
Circulating endothelial cells
Endothelial precursor cells
Myeloid derived suppressor cells
Soluble factors and transduction pathways
Exosomes and angiogenesis in MM
Proteasome inhibitors
Receptor tyrosine kinase inhibitors
Monoclonal antibodies
Combination therapies


1. Michael Medinger and Jakob Passweg  Division of Hematology, University Hospital Basel, Basel, Switzerland.
2. Napoleone M. A. Ferrara Moores Cancer Center, San Diego, United States.
3. Paul G. Murray  University of Birmingham, Birmingham, United Kingdom.
4. Roberto Ria and Angelo Vacca  Università degli Studi di Bari, Bari, Italy.
5. Paul G. Richardson  Dana-Farber Cancer Institute, Boston, United States.
6. Nicola Giuliani  Università degli Studi di Parma, Parma, Italy.
7. Pier Paolo Piccaluga  Bologna Univ, Dept Expt Diagnost & Special Med, Sch Med, I-40138 Bologna, Italy.
8. Evangelos Terpos and Meletios-Athanasios Dimopoulos  National and Kapodistrian University of Athens, Athens, Greece.
9. Ugo Testa  Istituto Superiore Di Sanita, Rome, Italy.
10. Thomas Pabst  UniversitätsSpital Bern, Bern, Switzerland.
11. Stefano Molica  Azienda Ospedaliera Pugliese-Ciaccio, Catanzaro, Italy.
12. Eduardo Magalhães Rego and Luciana Yamamoto de Almeida  Universidade de Sao Paulo - USP, Sao Paulo, Brazil.
13. Fabián Benencia  Ohio University, Athens, United States.
14. Peter Valent  Medical University of Vienna, Vienna, Austria.
15. Vasiliki Pappa  Attikon University General Hospital, Athens, Greece.
16. Giovanna Tosato  National Cancer Institute (NCI), Bethesda, United States.
17. Giuseppe Ingravallo  Università degli Studi di Bari, Facoltà di Medicina e Chirurgia, Bari, Italy.
18. Lucio Miele  LSU Health Sciences Center, New Orleans, LA, USA.
19. Eunice S. Wang  Roswell Park Cancer Institute, Buffalo, United States.
20. Federico Bussolino  Università degli Studi di Torino, Turin, Italy.
21. Maria Teresa Petrucci  Università degli Studi di Roma La Sapienza, Rome, Italy.
22. Ángeles García-Pardo and Javier Redondo-Muñoz  CSIC - Centro de Investigaciones Biológicas Margarita Salas (CIB), Madrid, Spain.
23. Alberto Rocci  Manchester University NHS Foundation Trust, Manchester, United Kingdom.
24. Toni Valković  Rijeka University, Rijeka, Croatia.
25. Sérgio Jerónimo Dias  University of Lisbon Faculty of Medicine, Institute of Molecular Medicine, Lisbon, Portugal.
26. Brigitte Bauvois  Sorbonne Universite, Paris, France.
27. Alicia Rodríguez-Barbero  Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain.
The list is arranged in no particular order and being updated.

Submission Deadline

31 Dec 2021

Submission Information

Articles of special issue are free of charge for article processing.
For Author Instructions, please refer to
For Online Submission, please login at
Submission Deadline: 31 Dec 2021
Contacts: Carl Zhou, Assistant Editor,

Published Articles

© 2016-2023 OAE Publishing Inc., except certain content provided by third parties